This is an image preview.
Start a Free Account
to view the full image.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Application of saRNA and mRNA for Gaucher disease treatment as protein replacement therapy

Download

(Left) When self-amplifying RNA (saRNA) is injected and delivered into cells, the translation of replicase takes place. The replicase uses the saRNA as a template and makes a negative saRNA strand, which in turn serves as a template for self-amplification by the replicase. Replicase recognizes sub-genomic promoter in the negative strand, so sgRNA is synthesized. Consequently, high levels of glucocerebrosidase are produced. (Right) When the mRNA is injected and delivered into the cells, it is translated into glucocerebrosidase protein. Ultimately, the glucocerebrosidase produced breaks down the GlcCer into glucose and ceramide leading to the normal condition.

Abbreviations: saRNA, self-amplifying RNA; mRNA, messenger RNA; sgPr, sub-genomic promoter; GD, Gaucher disease; GCase, glucocerebrosidase; GlcCer, glucosylceramide.

(Source: Feng S, Rcheulishvili N, Jiang X, et al. A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase-targeted mRNA/saRNA approach. Int J Biol Sci 2024;20[6]:2111-29. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0.)